ATE350026T1 - Erhaltung von körpereigenen proteinen - Google Patents

Erhaltung von körpereigenen proteinen

Info

Publication number
ATE350026T1
ATE350026T1 AT02716527T AT02716527T ATE350026T1 AT E350026 T1 ATE350026 T1 AT E350026T1 AT 02716527 T AT02716527 T AT 02716527T AT 02716527 T AT02716527 T AT 02716527T AT E350026 T1 ATE350026 T1 AT E350026T1
Authority
AT
Austria
Prior art keywords
alpha
skeletal muscle
preserving
kga
ammonium
Prior art date
Application number
AT02716527T
Other languages
English (en)
Inventor
Lars Wiklund
Torbjoern Karlsson
Anders Nordgren
Original Assignee
Lars Wiklund
Torbjoern Karlsson
Anders Nordgren
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lars Wiklund, Torbjoern Karlsson, Anders Nordgren filed Critical Lars Wiklund
Application granted granted Critical
Publication of ATE350026T1 publication Critical patent/ATE350026T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT02716527T 2001-01-31 2002-01-28 Erhaltung von körpereigenen proteinen ATE350026T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/773,394 US20020147237A1 (en) 2001-01-31 2001-01-31 Preservation of bodily protein

Publications (1)

Publication Number Publication Date
ATE350026T1 true ATE350026T1 (de) 2007-01-15

Family

ID=25098127

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02716527T ATE350026T1 (de) 2001-01-31 2002-01-28 Erhaltung von körpereigenen proteinen

Country Status (5)

Country Link
US (1) US20020147237A1 (de)
EP (1) EP1363615B1 (de)
AT (1) ATE350026T1 (de)
DE (1) DE60217302D1 (de)
WO (1) WO2002060429A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL368573A1 (en) * 2004-06-17 2005-12-27 Sgp & Sons Ab Pharmaceutical compound influencing growth and mineralization processes in the axial and the appendicular skeleton as well as bone diseases of mature years among humans and animals as well as application of the pharmaceutical compound in the process of growth and mineralization of axial and appendicular skeleton and bone diseases of mature years among humans and animals

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987003806A1 (en) * 1985-12-18 1987-07-02 Veech Richard L Parenteral nutrition therapy with amino acids
SE8704217D0 (sv) * 1987-10-29 1987-10-29 Vinnars Erik Ab Aminosyrakomposition for parenteral neringstillforsel
SE462463B (sv) * 1988-12-02 1990-07-02 Decken Alexandra V D Livs- och fodermedel innehaallande ketosyror
US5219330A (en) * 1991-11-26 1993-06-15 Imed Corporation Method and apparatus for preprogrammed infusion of iv medicaments
SE9201584D0 (sv) * 1992-05-20 1992-05-20 Vinnars Erik Ab Use of alpha-ketoglutarate
JP3467290B2 (ja) * 1993-08-12 2003-11-17 第一製網株式会社 養殖海苔の雑藻・病害駆除剤

Also Published As

Publication number Publication date
DE60217302D1 (de) 2007-02-15
EP1363615B1 (de) 2007-01-03
US20020147237A1 (en) 2002-10-10
EP1363615A1 (de) 2003-11-26
WO2002060429A1 (en) 2002-08-08

Similar Documents

Publication Publication Date Title
PT88985A (pt) Processo para a preparacao de composicoes farmaceuticas nasais e ou oftalmicas contendo azelastina
FI920026A0 (fi) Farmaceutisk komposition anvaendbar som avmagringsmedicin.
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
MD1699F2 (ro) Compoziţie apoasă a hormonului somatotrop uman şi procedeu de prevenire a denaturării ei
ATE113834T1 (de) Zusammensetzung zur behandlung der schizophrenie.
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
EA199900499A1 (ru) Фармацевтическая композиция, включающая соединение, обладающее анти-xa активностью, и соединение антагонист агрегации тромбоцитов
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
CA2060560A1 (en) Method for insuring adequate intracellular glutathione in tissue
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
CA2420640A1 (en) Combination preparations of 3-n-formyl hydroxy amino propyl phosphonic acid derivatives or 3-n-acetyl hydroxy amino propyl phosphonic acid derivatives together with special pharmaceutical active ingredients
ATE350026T1 (de) Erhaltung von körpereigenen proteinen
EP0373771A3 (de) Neue pharmazeutische Anwendungen von Cystatinen
HUP9902415A2 (hu) Azonnal felszabaduló szilárd beadási formák és eljárás azok előállítására
ATE401394T1 (de) Verbesserte dnase flüssige lösungen
EA199700150A1 (ru) КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ ПО ПОВОДУ ВИЧ ИНФЕКЦИИ С ИСПОЛЬЗОВАНИЕМ ИНГИБИТОРА ПРОТЕАЗЫ ВИЧ ИНДИНАВИРА И ИНГИБИТОРА ОБРАТНОЙ ТРАНСКРИПТАЗЫ 3TC, НЕОБЯЗАТЕЛЬНО СОВМЕСТНО С AZT, ddI ИЛИ ddC
IE840977L (en) Pharmaceutical preparations
DE69729201T2 (de) Sulfonfluoride zur behandlung von der alzheimerischen krankheit
UA41326C2 (uk) Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань
RU95105249A (ru) Гидрохлорид ng монометил-l-аргинина, способы его получения, способ получения фармацевтического препарата и способ лечения
WO2001028578A3 (en) A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
IT8348383A0 (it) Enzima simile a pepsina da leucocito umano, procedimento per prepararlo, e composizione terapeutica che lo contiene come ingrediente attivo

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties